<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[18, 20] melanoma.<br>[22, 31] Nearly 2000 patients with stage IIB and III melanoma<br>[140, 142] 713 patients<br></td>
<td width=33%>
[18, 20] melanoma.<br>[22, 31] Nearly 2000 patients with stage IIB and III melanoma<br>[140, 142] 713 patients<br></td>
<td width=33%>
[18, 20] melanoma.<br>[22, 51] Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter, randomized trials, conducted by the Eastern Cooperative Oncology Group and the Intergroup,<br>[140, 143] 713 patients randomized<br>[265, 274] ulceration, recurrent disease at entry, enrollment in<br>[275, 278] , and age<br>[278, 282] > 49 years.<br>[315, 323] patients with high-risk resected melanoma,<br></td>
</tr>
